- For Print
- March 27, 2025
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for the oral anticoagulant warfarin (generic name: warfarin potassium) in Japan to Sawai Pharmaceutical Co., Ltd. (Headquarters: Osaka, “Sawai”).
Warfarin has been widely used by patients in Japan for a long time since its launch in 1962. Eisai has determined that divesting rights for warfarin to Sawai is the most optimal choice to continue contributing to a greater number of patients. Under the terms of the agreement, Eisai will receive 4.5 billion yen for the transfer, and proceed with transfer of the marketing capability during a transfer period ending March 31 2026, followed by the transfer of the manufacturing and marketing approval. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2025.
Driven by our hhc concept, Eisai strives to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas: Neurology, Oncology and Global Health. As an hhceco company, Eisai aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities by creating solutions through building an ecosystem in collaboration with other industries.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
[Notes to editors]
1. About Sawai Pharmaceutical Co., Ltd.
Sawai Pharmaceutical Co., Ltd. is a pharmaceutical company established in 1948 with the corporate philosophy of "Always Putting Patients First”. It markets approximately 800 types of prescription pharmaceuticals, including treatments for lifestyle-related diseases (such as hypertension, dyslipidemia, diabetes) and anticancer drugs, contributing to people's health as a leading company in generic drugs.
For more information, please visit https://global.sawai.co.jp/